Cefobid Side Effects

Generic Name: cefoperazone

Note: This page contains information about the side effects of cefoperazone. Some of the dosage forms included on this document may not apply to the brand name Cefobid.

Not all side effects for Cefobid may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Applies to cefoperazone: injectable powder for injection


A case of occupational contact dermatitis due to cephalosporin allergy has been reported in a nurse who prepared cephalosporin solutions for administration to patients. The dermatitis resolved after the nurse stopped preparing the solutions.

Hypersensitivity reactions, often manifested as skin rashes, are common with cefoperazone and may require drug discontinuation. Drug fever and changes in Coombs' tests have also been reported. Allergic cross-reactivity may occur in patients allergic to penicillin. Cephalosporin class antibiotics have been associated with anaphylaxis, Stevens-Johnson syndrome, erythema multiforme, and toxic epidermal necrolysis.


The frequent occurrence of diarrhea is thought to be due to the disturbance of intestinal flora from high biliary concentrations of cefoperazone (the active ingredient contained in Cefobid) In a study evaluating the intestinal side effects of cefoperazone, Clostridium difficile was found in the stool of several patients with diarrhea. In at least three of these cases no treatment was necessary and symptoms resolved.

Gastrointestinal side effects have included nausea, vomiting and diarrhea, the latter being the most frequent. Clostridium difficile has been documented in some patients receiving cefoperazone.


Hepatic side effects have included alterations in serum transaminases and alkaline phosphatase in 5% to 10% of patients, but drug discontinuation was usually not necessary. These changes are usually mild and transient and return to normal following completion of therapy. Cephalosporins as a class have been associated with hepatic dysfunction including cholestasis.


The effect of cefoperazone (the active ingredient contained in Cefobid) on hemostasis has been evaluated in at least one study and reported in several cases. In most of these cases, the patient had normal coagulation parameters, prothrombin time and partial thromboplastin time prior to starting cefoperazone therapy. Within several days to weeks, prolongation of prothrombin time and partial thromboplastin time developed. Bleeding occurred in some cases. Administration of vitamin K or fresh frozen plasma corrected the changes in most of these patients. Cefoperazone was continued in several patients.

Hematologic abnormalities have included eosinophilia, neutropenia, decreases in hemoglobin and hematocrit, thrombocytopenia, hypoprothrombinemia, and leukopenia. In most cases, these alterations do not require drug discontinuation or dosage reduction. Cephalosporins as a class have been associated with aplastic anemia, hemolytic anemia, prolonged prothrombin time, hemorrhage, neutropenia, pancytopenia, and agranulocytosis.


Renal side effects have included transient elevations of BUN and creatinine, and acute interstitial nephritis with renal failure. Cephalosporins as a class have been associated with renal dysfunction and toxic nephropathy.


Local side effects have included pain after intramuscular injection and phlebitis after intravenous infusion.


Dermatologic side effects associated with cephalosporin class antibiotics have included rash, Stevens-Johnson syndrome, erythema multiforme, and toxic epidermal necrolysis.

Nervous system

Nervous system side effects associated with some cephalosporins have included seizures in renally impaired patients.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.